SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...
Presentation highlights Nurix’s innovation and leadership in targeted protein modulation, including ligase inhibition Unique mechanism of action, an intramolecular glue, locks the E3 ligase Casitas ...
Unique mechanism of action, an intramolecular glue, locks the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) in a closed inactive state Phase 1 trial ongoing as monotherapy and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results